Dyne Therapeutics (DYN) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precigen (PGEN) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 127.8% versus a gain of 14.5%. Over five years, PGEN leads with a +62.2% price change compared with +7.3% for DYN. Dyne Therapeutics is the larger company by market cap ($2.98 billion vs $2.70 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYN | PGEN |
|---|---|---|
| Share price | $15.97 | $7.54 |
| Market cap | $2.98B | $2.70B |
| 1-day change | +3.70% | -0.13% |
| YTD return | -18.35% | +80.38% |
| 1-year return | +14.48% | +127.79% |
| 5-year return | +7.33% | +62.15% |
| EPS (TTM) | $-3.30 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | +146.73% |
| Net income (latest FY) | $-446.21M | $-250.64M |
| Operating margin | — | -1141.13% |
| Net margin | — | -2588.21% |
| 52-week high | $27.31 | $8.98 |
| 52-week low | $13.73 | $2.99 |
| Distance from 52-week high | -41.51% | -16.04% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +125.42% | +81.03% |
| Average volume | 2.77M | 5.03M |
| Shares outstanding | 186.75M | 358.04M |
| Employees | 289 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed DYN by 113.3 percentage points over the past year.
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 289 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
DYN vs PGEN FAQ
Which is bigger, Dyne Therapeutics or Precigen?
Dyne Therapeutics (DYN) is larger, with a market capitalization of $2.98B compared with $2.70B for Precigen (PGEN).
Which stock has performed better over the past year, DYN or PGEN?
PGEN returned +127.79% over the past 12 months, compared with +14.48% for DYN (price return, excluding dividends). Past performance does not predict future results.
Are Dyne Therapeutics and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.